Abstract
Background Intermittent fasting or calorie restriction (CR) diets provide anti-inflammatory and neuroprotective advantages in models of multiple sclerosis (MS); data in humans are sparse.
Methods We conducted a randomized-controlled feeding study of different CR diets in 36 people with MS over 8 weeks. Patients were randomized to receive either: a daily CR diet (22% reduction in calories, 7 days/week), an intermittent CR diet (75% reduction, 2 days/week; 100%, 5 days/week), or a weight-stable diet (100%, 7 days/week). Untargeted metabolomics was performed on plasma samples at weeks 0, 4 and 8 at Metabolon Inc (Durham, NC). Flow cytometry of cryopreserved peripheral blood mononuclear cells at weeks 0 and 8 were used to identify CD4+ and CD8+ T cell subsets including effector memory, central memory, and naïve cells.
Results 31 (86%) completed the trial. Over time, individuals randomized to intermittent CR had significant reductions in CD4+CM -4.87%; 95%CI: -8.59%, -1.15%; p=0.01), CD4+EM (−3.82%; 95%CI: -7.44, - 0.21; p=0.04), and CD8+EM (−6.96%; 95%CI: -11.96, -1.97; p=0.006) with proportional increases in naïve subsets (CD4+Naïve: 5.81%; 95%CI: -0.01, 11.63%; p=0.05; CD8+Naïve: 10.11%; 95%CI: 3.30, 16.92%; p=0.006). No changes were observed for daily CR or weight-stable diets. Larger within-person changes in lysophospholipid and lysoplasmalogen metabolites in intermittent CR were associated with larger reductions in memory T cell subsets and larger increases in naïve T cell subsets.
Conclusions In people with MS, an intermittent CR diet was associated with reduction in memory T cell subsets. The observed changes may be mediated by changes in specific classes of lipid metabolites.
Trial Registration This study is registered on Clinicaltrials.gov with identifier NCT02647502.
Funding National MS Society, NIH, Johns Hopkins Catalyst Award
Competing Interest Statement
Dr. Fitzgerald, Dr. Bhargava, Mr. Smith, Ms. Henry-Barron, Ms. Vizthum, Dr. Cassard, Dr. Kappogiannis, Mr. Sullivan, and Dr. Baer report no disclosures Dr. Kornberg has received consulting fees from Biogen Idec, Janssen Pharmaceuticals, Novartis, OptumRx, and TG Therapeutics. Dr. Calabresi has received consulting fees from Disarm, NervGen, and Biogen and is PI on grants to JHU from Genentech. Dr. Mowry has grants from Biogen, is site PI for studies sponsored by Biogen and Genentech, has received free medication for a clinical trial from Teva, and receives royalties for editorial duties from UpToDate
Clinical Trial
NCT02647502
Funding Statement
National MS Society, NIH, Johns Hopkins Catalyst Award
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
A Johns Hopkins Institutional Review Board
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
All data produced in the present study may be available upon reasonable request to the authors with appropriate data sharing requests in place.
